What is VSEE HEALTH INC WTS 29's earnings per share (EPS)?

VSEE HEALTH INC WTS 29 (VSEEW) reported diluted earnings per share of -$0.73 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

VSEE HEALTH INC WTS 29 (VSEEW) Financials

VSEEW

FY2025 annual

Revenue $14.6M +40.3% YoY

Net Income -$14.7M +74.5% YoY

EPS (Diluted) -$0.73 YoY not available

Free Cash Flow -$3.5M +40.5% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VSEEW SEC filings page.

VSEE HEALTH INC WTS 29 (VSEEW) reported $14.6M in revenue for fiscal year 2025, up 40.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI VSEEW FY2025 2026-08-30

Revenue expansion is not yet translating into operating viability: financing, not internal cash generation, is supporting the balance sheet.

Cash conversion remains weak despite a smaller loss: in FY2025, net loss was -$14.7M while operating cash flow was -$3.4M, so reported earnings and cash usage diverged materially. The simultaneous $8.4M financing inflow indicates that external capital, rather than operations, supplied the cash needed during the year.

Revenue reached $14.6M in FY2025, but gross margin fell to 50.3% from 68.9% in FY2024, showing that growth came with a substantially less favorable cost structure. Even after the prior year's exceptionally large operating loss, the latest operating margin remained -65.6%.

Balance-sheet flexibility improved but remains limited: equity moved from a near-zero deficit in FY2024 to $5.5M in FY2025, while current liabilities were still $16.2M against $8.4M of current assets. The current ratio of 0.5x therefore points to short-term obligations exceeding readily available current resources, even after financing restored positive equity.

Financial Health Signals

Financial health score not available

VSEE HEALTH INC WTS 29 does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Neutral

5/9

VSEE HEALTH INC WTS 29 passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

VSEE HEALTH INC WTS 29 reported a net loss of $14.7M while operations used $3.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

VSEE HEALTH INC WTS 29 reported an operating loss of $9.6M against $2.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.6M

YoY+48.0%

QoQ-50.6%

VSEE HEALTH INC WTS 29 generated $1.6M in revenue in Q2 2026. This represents an increase of 48.0% from the same quarter a year earlier. Against the prior quarter it is down 50.6%.

EBITDA

-$2.1M

YoY-125.2%

QoQ+11.6%

VSEE HEALTH INC WTS 29's EBITDA was -$2.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 125.2% from the same quarter a year earlier. Against the prior quarter it is up 11.6%.

EPS (Diluted)

-$0.06

QoQ-20.0%

VSEE HEALTH INC WTS 29 earned -$0.06 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 20.0%.

Net Income

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.2M

YoY-270.6%

QoQ+49.7%

VSEE HEALTH INC WTS 29 recorded an outflow of $1.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 270.6% from the same quarter a year earlier. Against the prior quarter it is up 49.7%.

Cash & Debt

$454K

YoY+55.7%

QoQ-66.3%

5Y CAGR+42.6%

VSEE HEALTH INC WTS 29 held $454K in cash against $782K in long-term debt as of Q2 2026, with $8.1M of liabilities due within a year.

Shares Outstanding

57M

QoQ+16.6%

VSEE HEALTH INC WTS 29 had 57M shares outstanding in Q2 2026. Against the prior quarter it is up 16.6%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

13.2%

YoY-45.1pp

QoQ-24.7pp

VSEE HEALTH INC WTS 29's gross margin was 13.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 45.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 24.7 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not reported for Q2 2026.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

Share Buybacks

YoY-100.0%

QoQ-100.0%

VSEE HEALTH INC WTS 29 repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Capital Expenditures

$73K

YoY+516.9%

QoQ+173.8%

VSEE HEALTH INC WTS 29 invested $73K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 516.9% from the same quarter a year earlier. Against the prior quarter it is up 173.8%.

R&D Spending

Not reported for Q2 2026.

VSEEW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VSEEW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Revenue	$15.0M	$14.6M+40.3%	$10.4M+80.7%	$5.8M	N/A
Cost of Revenue	$8.7M	$7.3M+123.9%	$3.2M+67.8%	$1.9M	N/A
Gross Profit	$6.3M	$7.4M+2.5%	$7.2M+87.3%	$3.8M	N/A
SG&A Expenses	$11.0M	$10.0M+53.1%	$6.6M+445.0%	$1.2M	N/A
Operating Income	-$11.9M	-$9.6M+84.6%	-$62.2M-3217.2%	-$1.9M+47.9%	-$3.6M
EBITDA	N/A	-$7.0M+88.5%	-$60.8M-3147.7%	-$1.9M	N/A
Interest Expense	$2.7M	$2.8M+1229.7%	$211K+10.5%	$191K+51.9%	$126K
Income Tax	$4K	$14K+100.8%	-$1.6M-189.4%	$1.8M+882.0%	$187K
Net Income	N/A	-$14.7M+74.5%	-$57.7M-1433.4%	-$3.8M-16.1%	-$3.2M
EPS (Basic)	N/A	-$0.73+87.1%	-$5.65-1386.8%	-$0.38-52.0%	-$0.25
EPS (Diluted)	—	-$0.73	-$5.65	-$0.38-52.0%	-$0.25
Diluted Shares (Avg)	N/A	20M	10M	10M-21.5%	13M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$1.6M+48.0%	$3.2M-4.9%	$6.3M+67.7%	$4.0M+18.7%	$1.1M-38.3%	$3.3M+104.9%	$3.7M+151.6%	$3.4M+134.1%
Cost of Revenue	$1.4M+208.0%	$2.0M+34.2%	$3.5M+141.6%	$1.9M+102.6%	$440K-9.6%	$1.5M+278.4%	$1.4M	$941K+96.8%
Gross Profit	$206K-66.5%	$1.2M-35.6%	$2.8M+17.9%	$2.1M-25.5%	$615K-20.8%	$1.9M+50.6%	$2.4M+120.7%	$2.8M+191.8%
SG&A Expenses	$2.3M+30.7%	$2.4M+20.1%	$3.4M-5.4%	$2.9M+31.5%	$1.7M+203.4%	$2.0M+864.2%	$3.6M+1771.2%	$2.2M+678.8%
Operating Income	-$2.7M-73.3%	-$3.0M-62.4%	-$4.1M-36.7%	-$2.1M+96.5%	-$1.6M-66.9%	-$1.8M-1859.9%	-$3.0M-2536.4%	-$58.3M-16411.1%
EBITDA	-$2.1M-125.2%	-$2.3M-96.5%	-$3.5M-93.7%	-$1.4M+97.6%	-$913K+1.5%	-$1.2M-1231.4%	-$1.8M	-$58.2M-16393.6%
Interest Expense	$9K-95.8%	$113K+1124.4%	$1.8M+815.2%	$756K+555.1%	$222K-35.0%	$9K-0.8%	-$255K-339.9%	$115K+217.8%
Income Tax	-$18K-1135.8%	$24K+75.8%	-$2K-106.5%	$0-100.0%	$2K+100.1%	$14K	$27K	$9K+103.8%
Net Income	N/A	-$2.6M+34.3%	-$7.9M-144.7%	-$290K+99.5%	-$2.6M-312.1%	-$4.0M-6407.9%	-$3.2M-26.3%	-$53.9M-28316.8%
EPS (Basic)	-$0.06+62.5%	-$0.05+79.2%	-$0.31-135.2%	-$0.02+99.4%	-$0.16-33.3%	-$0.24-2500.0%	$0.88+438.5%	-$3.58-17800.0%
EPS (Diluted)	-$0.06	-$0.05	-$0.31	-$0.02+99.4%	-$0.16	-$0.24	$0.88	-$3.58
Diluted Shares (Avg)	54M	48M	N/A	17M+9.8%	16M	16M	N/A	15M

Not reported in any period shown, so not listed: R&D Expenses.

VSEEW Balance Sheet

VSEEW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Total Assets	$22.4M+12.1%	$20.0M+2381.1%	$806K-89.4%	$7.6M
Current Assets	$8.4M+176.9%	$3.0M+276.6%	$802K+649.7%	$107K
Cash & Equivalents	$5.1M+1449.0%	$326K+174.7%	$119K+11.0%	$107K
Short-Term Investments	$0	$0	$0	$0
Accounts Receivable	$2.2M+30.6%	$1.7M+184.4%	$603K+55.0%	$389K
Long-Term Investments	$0	$0	$0	$0
Goodwill	$4.9M0.0%	$4.9M	N/A	N/A
Total Liabilities	$17.0M-15.2%	$20.0M+53.1%	$13.1M-13.2%	$15.1M
Current Liabilities	$16.2M-14.5%	$19.0M+272.4%	$5.1M+54.9%	$3.3M
Non-Current Liabilities	$716K-28.4%	$1.0M-87.4%	$8.0M-32.3%	$11.8M
Long-Term Debt	$594K0.0%	$594K+170.0%	$220K	N/A
Total Equity	$5.5M+29591.4%	-$18K+99.8%	-$12.3M-65.2%	-$7.4M
Retained Earnings	-$82.4M-21.7%	-$67.7M-576.9%	-$10.0M-60.3%	-$6.2M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$16.7M-8.1%	$19.0M-2.0%	$22.4M+12.1%	$18.7M-16.1%	$18.2M-76.8%	$19.4M+1298.2%	$20.0M+2381.1%	$22.3M+174.0%
Current Assets	$3.3M+27.6%	$4.8M+57.2%	$8.4M+176.9%	$3.7M-15.1%	$2.6M-16.8%	$3.1M+425294.1%	$3.0M+276.6%	$4.4M+24208.2%
Cash & Equivalents	$454K+55.7%	$1.3M+228.2%	$5.1M+1449.0%	$473K-79.7%	$292K-73.6%	$410K+56546.7%	$326K+174.7%	$2.3M+458940.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$2.2M+38.0%	$2.7M+44.3%	$2.2M+30.6%	$2.6M+152.1%	$1.6M+75.1%	$1.9M	$1.7M+184.4%	$1.0M
Long-Term Investments	$750K	$750K	$0	$0	$0	$0	$0	$0
Goodwill	$4.9M0.0%	$4.9M0.0%	$4.9M0.0%	$4.9M0.0%	$4.9M-92.0%	$4.9M	$4.9M	$4.9M
Total Liabilities	$9.1M-61.8%	$12.7M-44.5%	$17.0M-15.2%	$24.3M+13.6%	$23.9M-6.0%	$22.9M+56.6%	$20.0M+53.1%	$21.4M+23.6%
Current Liabilities	$8.1M-64.9%	$11.8M-46.3%	$16.2M-14.5%	$23.4M+15.8%	$23.1M-4.4%	$22.0M+145.1%	$19.0M+272.4%	$20.2M+301.2%
Non-Current Liabilities	$1.0M+17.8%	$901K-1.0%	$716K-28.4%	$860K-24.0%	$888K-34.9%	$910K-83.9%	$1.0M-87.4%	$1.1M-90.8%
Long-Term Debt	$782K+31.6%	$782K+31.6%	$594K0.0%	$589K-0.8%	$594K0.0%	$594K	$594K+170.0%	$594K
Total Equity	$7.6M+232.4%	$6.3M+280.8%	$5.5M+29591.4%	-$5.6M-697.5%	-$5.7M-110.8%	-$3.5M+73.6%	-$18K+99.8%	$933K+110.2%
Retained Earnings	-$84.2M-13.3%	-$85.0M-18.6%	-$82.4M-21.7%	-$74.6M-15.6%	-$74.3M-602.5%	-$71.7M-621.0%	-$67.7M-576.9%	-$64.5M-766.5%

Not reported in any period shown, so not listed: Inventory.

VSEEW Cash Flow Statement

VSEEW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Operating Cash Flow	-$6.3M	-$3.4M+40.5%	-$5.8M-815.2%	-$633K+54.5%	-$1.4M
Depreciation & Amortization	N/A	$2.6M+95.5%	$1.3M+195101.6%	$678	N/A
Stock-Based Compensation	N/A	$1.1M+25.4%	$897K	$0	N/A
Capital Expenditures	$130K	$30K-45.8%	$55K+1174.9%	$4K	N/A
Free Cash Flow	-$6.4M	-$3.5M+40.5%	-$5.8M-817.7%	-$637K	N/A
Investing Cash Flow	-$143K	-$30K-14.5%	-$26K-503.1%	-$4K	N/A
Financing Cash Flow	$6.8M	$8.4M+39.7%	$6.0M+1047.3%	$525K	N/A
Share Buybacks	$50K	$44-99.1%	$5K-99.9%	$6.8M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.2M-261.6%	-$2.5M-456.7%	-$1.9M+35.2%	-$755K-241.4%	-$325K+89.8%	-$440K-176.0%	-$3.0M-2624.7%	-$221K-353.0%
Depreciation & Amortization	$640K-0.4%	$647K-0.1%	$646K-3.8%	$652K+599.2%	$643K+12720.9%	$647K+104598.5%	$672K+237251.9%	$93K+48716.2%
Stock-Based Compensation	N/A	$441K+12.5%	N/A	N/A	N/A	$392K	N/A	$349K
Capital Expenditures	$73K+516.9%	$27K+125.3%	$7K+50.3%	$23K+356.1%	-$12K-67.7%	$12K+35.8%	$5K+189.4%	$5K
Free Cash Flow	-$1.2M-270.6%	-$2.5M-448.0%	-$1.9M+35.1%	-$777K-243.9%	-$336K+89.5%	-$452K-179.3%	-$3.0M-2588.6%	-$226K-363.2%
Investing Cash Flow	-$2K+44.3%	-$127K-967.6%	-$7K-50.3%	-$7K-46.4%	-$4K+53.0%	-$12K-35.8%	-$5K-189.4%	-$5K
Financing Cash Flow	$499K+137.8%	-$1.3M-350.1%	$6.7M+587.9%	$943K-34.8%	$210K-94.2%	$536K	$978K+1296.9%	$1.4M+972.1%
Share Buybacks	$0-100.0%	$50K	$0-100.0%	$0	$44	$0	$5K	N/A

Not reported in any period shown, so not listed: Dividends Paid.

VSEEW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

VSEEW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K
Gross Margin	50.3%-18.6pp	68.9%+2.4pp	66.5%	N/A
Operating Margin	-65.5%	-596.4%	-32.5%	N/A
Net Margin	-100.6%	-553.7%	-65.3%	N/A
Return on Equity	-269.8%	N/A	N/A	N/A
Return on Assets	-65.6%+223.0pp	-288.6%+178.4pp	-467.0%-424.5pp	-42.5%
Current Ratio	0.52+0.4x	0.160.0x	0.16+0.1x	0.03
Debt-to-Equity	0.11	N/A	N/A	N/A
Asset Turnover	0.65+0.1x	0.52-6.6x	7.16	N/A
FCF Margin	-23.8%+32.3pp	-56.1%-45.0pp	-11.1%	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	13.2%-45.1pp	37.9%-18.1pp	44.8%-18.9pp	52.1%-30.9pp	58.3%+12.9pp	56.0%-20.2pp	63.8%-8.9pp	83.0%+16.4pp
Operating Margin	-172.7%	-94.1%-39.0pp	-66.1%+15.0pp	-51.7%	-147.5%	-55.1%-61.6pp	-81.1%-73.3pp	-1737.8%
Net Margin	N/A	-82.3%	-125.4%	-7.3%	-247.7%	-119.2%	-85.9%	-1607.5%
Return on Equity	N/A	-41.1%	-144.0%	N/A	N/A	N/A	N/A	-5778.7%
Return on Assets	N/A	-13.7%+6.7pp	-35.0%-19.0pp	-1.6%+240.3pp	-14.3%-13.5pp	-20.4%-24.9pp	-16.1%+299.2pp	-241.8%-239.5pp
Current Ratio	0.40+0.3x	0.41+0.3x	0.52+0.4x	0.16-0.1x	0.110.0x	0.14+0.1x	0.160.0x	0.22+0.2x
Debt-to-Equity	0.10	0.12	0.11	N/A	N/A	N/A	N/A	0.64
Asset Turnover	0.090.0x	0.170.0x	0.28+0.1x	0.21+0.1x	0.060.0x	0.17-1.0x	0.19-1.7x	0.150.0x
FCF Margin	-79.8%-47.9pp	-78.4%-64.8pp	-30.9%+48.9pp	-19.5%-12.8pp	-31.9%	-13.6%-48.8pp	-79.8%-72.3pp	-6.7%-3.3pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: The current ratio is below 1.0 (0.52), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Where VSEE HEALTH INC WTS 29 Ranks

Frequently Asked Questions

What is VSEE HEALTH INC WTS 29's annual revenue?

VSEE HEALTH INC WTS 29 (VSEEW) reported $14.6M in total revenue for fiscal year 2025. This represents a 40.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is VSEE HEALTH INC WTS 29's revenue growing?

VSEE HEALTH INC WTS 29 (VSEEW) revenue grew by 40.3% year-over-year, from $10.4M to $14.6M in fiscal year 2025.

Is VSEE HEALTH INC WTS 29 profitable?

No, VSEE HEALTH INC WTS 29 (VSEEW) reported a net income of -$14.7M in fiscal year 2025.

What is VSEE HEALTH INC WTS 29's EBITDA?

VSEE HEALTH INC WTS 29 (VSEEW) had EBITDA of -$7.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does VSEE HEALTH INC WTS 29 have?

As of fiscal year 2025, VSEE HEALTH INC WTS 29 (VSEEW) had $5.1M in cash and equivalents against $594K in long-term debt.

What is VSEE HEALTH INC WTS 29's gross margin?

VSEE HEALTH INC WTS 29 (VSEEW) had a gross margin of 50.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is VSEE HEALTH INC WTS 29's operating margin?

VSEE HEALTH INC WTS 29 (VSEEW) had an operating margin of -65.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is VSEE HEALTH INC WTS 29's return on equity (ROE)?

VSEE HEALTH INC WTS 29 (VSEEW) has a return on equity of -269.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is VSEE HEALTH INC WTS 29's free cash flow?

VSEE HEALTH INC WTS 29 (VSEEW) recorded an outflow of $3.5M in free cash flow during fiscal year 2025. This represents a 40.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is VSEE HEALTH INC WTS 29's operating cash flow?

VSEE HEALTH INC WTS 29 (VSEEW) recorded an outflow of $3.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are VSEE HEALTH INC WTS 29's total assets?

VSEE HEALTH INC WTS 29 (VSEEW) had $22.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are VSEE HEALTH INC WTS 29's capital expenditures?

VSEE HEALTH INC WTS 29 (VSEEW) invested $30K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Does VSEE HEALTH INC WTS 29 buy back shares?

Yes, VSEE HEALTH INC WTS 29 (VSEEW) spent $44 on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does VSEE HEALTH INC WTS 29 have outstanding?

VSEE HEALTH INC WTS 29 (VSEEW) had 47M shares outstanding as of fiscal year 2025.

What is VSEE HEALTH INC WTS 29's current ratio?

VSEE HEALTH INC WTS 29 (VSEEW) had a current ratio of 0.52 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is VSEE HEALTH INC WTS 29's debt-to-equity ratio?

VSEE HEALTH INC WTS 29 (VSEEW) had a debt-to-equity ratio of 0.11 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is VSEE HEALTH INC WTS 29's return on assets (ROA)?

VSEE HEALTH INC WTS 29 (VSEEW) had a return on assets of -65.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does VSEE HEALTH INC WTS 29's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, VSEE HEALTH INC WTS 29 (VSEEW) held $5.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $3.4M over that year. Dividing the one by the other, the reported balance equals about 18 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is VSEE HEALTH INC WTS 29's Piotroski F-Score?

VSEE HEALTH INC WTS 29 (VSEEW) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are VSEE HEALTH INC WTS 29's earnings high quality?

VSEE HEALTH INC WTS 29 (VSEEW) reported a net loss of $14.7M while operations used $3.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can VSEE HEALTH INC WTS 29 cover its interest payments?

VSEE HEALTH INC WTS 29 (VSEEW) reported an operating loss of $9.6M against $2.8M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.